The main oral treatment for COVID-19 is Paxlovid, a combination antiviral pill that the NIH ranks as the top recommended therapy for non-hospitalized adults at risk of severe illness. A second oral option, molnupiravir, is available when Paxlovid isn’t suitable. Both must be started within five days of your first symptoms to work effectively.
Paxlovid: The Preferred Option
Paxlovid is a combination of two drugs packaged together. The first blocks a key enzyme the virus needs to assemble copies of itself. The second slows your body’s breakdown of the first drug, keeping it active longer. You take three tablets (two of one, one of the other) twice a day, morning and evening, for five days. Treatment should start as soon as possible after a positive test and within five days of symptom onset, even if your symptoms are mild.
To be eligible, you need to be an adult (or at least 12 years old and weighing at least 88 pounds) with mild to moderate COVID-19, meaning you aren’t sick enough to need hospitalization. You also need at least one risk factor for progressing to severe disease. Your prescriber makes that call based on your medical history, using CDC guidance on conditions like obesity, diabetes, heart disease, chronic lung disease, and immunocompromising conditions, among others.
Drug Interactions With Paxlovid
The component of Paxlovid that keeps the antiviral active in your system also interferes with how your liver processes many other medications. This is the biggest practical barrier to taking it. Several common drug classes are affected:
- Blood thinners: Rivaroxaban must be avoided entirely due to increased bleeding risk. Apixaban requires a 50% dose reduction. Warfarin needs close monitoring.
- Statins: Cholesterol-lowering drugs like atorvastatin should be temporarily stopped for the five-day course.
- Calcium channel blockers: Blood pressure medications in this class may need dose reductions because of increased risk of low blood pressure and slow heart rate.
- Sedatives: Benzodiazepines like alprazolam, clonazepam, and diazepam require dose reductions due to the risk of excessive sedation.
- Hormonal birth control: Oral contraceptives may become less effective, so backup contraception is needed during treatment.
- Certain mental health medications: Quetiapine doses must be cut to roughly one-sixth of the normal amount.
If you take multiple medications, your prescriber will need to review each one. In some cases, the interactions make Paxlovid unsafe, which is where the alternative comes in.
Molnupiravir: The Alternative
Molnupiravir works differently. Instead of blocking the virus’s assembly process, it inserts errors into the virus’s genetic code as it tries to copy itself, essentially corrupting the copies so they can’t function. The NIH recommends it only when Paxlovid (or the IV antiviral remdesivir) isn’t available, can’t be used, or isn’t clinically appropriate.
A large meta-analysis covering more than 1.6 million patients found that molnupiravir reduced the risk of death by 55% to 65% within 28 days. Its ability to prevent hospitalization, however, varied significantly by age. It was most effective at keeping people 75 and older out of the hospital, while younger adults (ages 45 to 74) saw little hospitalization benefit. Like Paxlovid, it needs to be started within five days of symptoms.
Symptom Rebound After Treatment
Some people experience a return of symptoms or test positive again shortly after finishing their antiviral course. This is commonly called “COVID rebound.” In a study of more than 11,000 Paxlovid-treated patients, about 3.5% tested positive again within the first week after treatment, and roughly 5.4% did within 30 days. Symptom rebound followed a similar pattern, with about 2.3% experiencing returning symptoms in the first week and 5.9% within a month.
Rebound rates were somewhat higher with molnupiravir: about 5.9% tested positive again within a week, rising to 8.6% over 30 days. In both cases, hospitalization after rebound was uncommon, under 1% for Paxlovid and about 1.4% for molnupiravir at 30 days. Rebound doesn’t mean the treatment failed. Most people recover without needing a second course.
Paying for Oral Antivirals
Paxlovid is no longer free through the government supply the way it was during the public health emergency. Out-of-pocket cost depends on your insurance. Pfizer runs a patient support program called PAXCESS that offers co-pay savings of up to $1,500 per prescription for commercially insured patients, potentially bringing the cost to $0. Patients on Medicare, Medicaid, TRICARE, or those who are uninsured have been able to access Paxlovid for free through a separate government patient assistance program operated by Pfizer. You can check eligibility and enroll at PAXCESSPatientPortal.com or by calling 1-877-219-7225.
Timing Matters More Than Anything
The single most important factor with oral COVID treatments is starting early. Both Paxlovid and molnupiravir are designed to work while the virus is still actively replicating in your body, which is why the window closes at five days after symptom onset. If you test positive and have risk factors for severe disease, contact a healthcare provider the same day if possible. Many telehealth services can prescribe these medications quickly, and pharmacies can often fill them within hours. Waiting to see if you get worse before seeking treatment narrows the window in which these drugs are effective.